<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:17:12Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10450072" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10450072</identifier>
        <datestamp>2023-08-26</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10450072</article-id>
              <article-id pub-id-type="pmcid">PMC10450072</article-id>
              <article-id pub-id-type="pmc-uid">10450072</article-id>
              <article-id pub-id-type="pmid">37620270</article-id>
              <article-id pub-id-type="pmid">37620270</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2023-072745</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2023-072745</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Anaesthesia</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1682</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>PeRiOperative Glucose PRAgMatic (PROGRAM) trial protocol and statistical analysis plan for comparing automated intraoperative reminders to standardise insulin administration in surgical patients at high risk of hyperglycaemia</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-105408940" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5544-8900</contrib-id>
                  <name>
                    <surname>Zapf</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-104460704" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9242-5177</contrib-id>
                  <name>
                    <surname>Patel</surname>
                    <given-names>Dev</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-105409031" contrib-type="author">
                  <name>
                    <surname>Henson</surname>
                    <given-names>Patrick</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-66126430" contrib-type="author">
                  <name>
                    <surname>McEvoy</surname>
                    <given-names>Matthew D</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-105409067" contrib-type="author">
                  <name>
                    <surname>Huang</surname>
                    <given-names>Eunice</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-67966558" contrib-type="author">
                  <name>
                    <surname>Wanderer</surname>
                    <given-names>Jonathan P</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-105409082" contrib-type="author">
                  <name>
                    <surname>Fowler</surname>
                    <given-names>Leslie</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-105409092" contrib-type="author">
                  <name>
                    <surname>Mccarthy</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-87642857" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0343-9823</contrib-id>
                  <name>
                    <surname>Freundlich</surname>
                    <given-names>Robert E</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-105410511" contrib-type="author">
                  <name>
                    <surname>Eden</surname>
                    <given-names>Svetlana</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-76236477" contrib-type="author">
                  <name>
                    <surname>Shotwell</surname>
                    <given-names>Matthew S</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-76234412" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6611-7998</contrib-id>
                  <name>
                    <surname>Kertai</surname>
                    <given-names>Miklos D</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>the PROGRAM Investigators</collab>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Department of Anesthesiology</institution>, <institution specific-use="Ringgold_12328">Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Department of Pediatric Surgery</institution>, <institution specific-use="Ringgold_12328">Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Department of Biostatistics</institution>, <institution specific-use="Ringgold_12328">Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Matthew Zapf; <email>matthew.a.zapf@vumc.org</email>
</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <issue>8</issue>
              <elocation-id>e072745</elocation-id>
              <history>
                <date date-type="received">
                  <day>21</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>14</day>
                  <month>8</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-08-23">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2023-072745.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2023-072745.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2023-072745.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Studies finding perioperative hyperglycaemia is associated with adverse patient outcomes in surgical procedures spurred the development of blood glucose guidelines at many institutions. In this trial, we will assess the implementation of a clinical decision support tool that is integrated into the intraoperative portion of our electronic health record and provides real-time best practice recommendations for intraoperative insulin dosing in surgical patients at high risk for hyperglycaemia.</p>
                </sec>
                <sec>
                  <title>Methods and design</title>
                  <p>We will assess this intervention using a sequential and repeated cross-over design at the institutional level with periods of time for wash-out, control and study intervention. The unit of analysis will be the surgical case. The primary outcome will be the frequency of hyperglycaemia (&gt;180 mg/dL (10 mmol/L)) at first postoperative anaesthesia care unit measurement. There are several prespecified secondary analyses focused on perioperative glycaemic control.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p>This protocol and statistical analysis plan describes the methodology, primary and secondary analyses. The PeRiOperative Glucose PRAgMatic (PROGRAM) trial was approved by the Vanderbilt University Institutional Review Board (IRB), Vanderbilt University Medical Center, Nashville, Tennessee, USA (IRB, 220991). The study results will be disseminated via publication in a peer-reviewed journal and presented at national scientific conferences. The results of PROGRAM trial will inform best practice for perioperative standardised insulin administration in surgical patients at high risk of hyperglycaemia.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT05426096" ext-link-type="uri">NCT05426096</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>surgery</kwd>
                <kwd>anaesthetics</kwd>
                <kwd>anaesthesia in cardiology</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institutes of Health (NIH)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>(T32GM108554) (Zapf NIH)</award-id>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution>NHLBI</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>K23HL148640</award-id>
                  <award-id>T32GM108554</award-id>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>(T32GM108554) (Zapf NIH)</award-id>
                  <award-id>NHLBI K23HL148640 (PI: Freundlich)</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>Evaluation of the effect an actionable tool that provides active insulin dosing guidelines to improve the control of hyperglycaemia in high-risk patients.</p>
                </list-item>
                <list-item>
                  <p>The intervention will test the intraoperative delivery of active insulin dosing guidelines through the electronic health record system, which automates access to standard institutional insulin dosing guidelines.</p>
                </list-item>
                <list-item>
                  <p>A sequential and repeated cross-over design at the institutional level with periods of time for wash-out, control and study intervention.</p>
                </list-item>
                <list-item>
                  <p>The nature of the study design and intervention does not allow blinding.</p>
                </list-item>
                <list-item>
                  <p>The trial is a single-centre study at a quaternary academic centre, which limits the generalisability of the results.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Poor intraoperative glucose control has been linked to multiple types of postoperative infections including surgical site infections and urinary tract infections.<xref rid="R1" ref-type="bibr">1–8</xref> Maintaining a blood glucose of less than 180 mg/dL (10 mmol/L) is associated with a reduced risk of infection and setting this target range minimises risks of hypoglycaemia as compared with stricter blood glucose targets.<xref rid="R5" ref-type="bibr">5 7 8</xref> Intraoperative control of hyperglycaemia is complicated by lack of knowledge of appropriate treatment goals and interventions, inattention secondary to the mental load of intraoperative management, glucose monitoring equipment availability or the time involved in measuring glucose and initiating insulin treatment.</p>
              <p>At our institution, a clinical decision support (CDS) reminder is triggered in the intraoperative portion of the electronic health record (EHR) to suggest that providers obtain glucose measurements in patients at high risk for hyperglycaemia (<xref rid="F1" ref-type="fig">figure 1</xref>). Appropriate use of this CDS reminder has been successful in reducing surgical site infections,<xref rid="R1" ref-type="bibr">1</xref> and a recent study demonstrated that when the reminder was removed there was a significant reduction in glucose monitoring which was improved on reinstitution of the glucose monitoring reminder.<xref rid="R9" ref-type="bibr">9</xref> We hope to improve on the CDS reminder by adding our departmental insulin dosing guidelines to the reminder (<xref rid="F2" ref-type="fig">figure 2</xref>). This automated insulin dosing reminder (AIDR) not only suggests the provider obtain a glucose, but also uses the last recorded glucose values in the EHR to propose appropriate insulin dosing to the anaesthesia care team.</p>
              <fig position="float" id="F1">
                <label>Figure 1</label>
                <caption>
                  <p>Current intraoperative clinical decision support (CDS) reminder at our institution. This CDS is triggered in the intraoperative portion of the electronic health record to suggest that providers obtain glucose measurements in patients at high risk for hyperglycaemia.</p>
                </caption>
                <graphic xlink:href="bmjopen-2023-072745f01" position="float"/>
              </fig>
              <fig position="float" id="F2">
                <label>Figure 2</label>
                <caption>
                  <p>Proposed clinical decision support (CDS) reminder tested in the study. This interactive CDS reminder will be tested in our study by adding our departmental insulin dosing guidelines. This automated insulin dosing reminder not only suggests the provider obtain a glucose, but also uses the last recorded glucose values in the electronic health record to propose appropriate insulin dosing to the anaesthesia care team.</p>
                </caption>
                <graphic xlink:href="bmjopen-2023-072745f02" position="float"/>
              </fig>
              <p>In this proposed study, we will assess the implementation of an AIDR. Our specific hypothesis is that by adding an AIDR containing a departmental insulin dosing guidelines that includes real-time data pertinent to the patient, in-room anaesthesia providers will deliver care that results in decreased rates of perioperative hyperglycaemia. In addition, the secondary analysis of detailed, prospectively collected data obtained in this study may help improve the perioperative insulin dosing best practices at our institution, and it could serve as a proof-of-concept model which could apply to other healthcare facilities managing surgical patients at high risk of hyperglycaemia.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <p>Our manuscript was prepared in accordance with Standard Protocol Items: Recommendations for Interventional Trials Outcomes (SPIRIT-Outcomes) guidelines (<xref rid="F3" ref-type="fig">figure 3</xref> and SPIRIT-Outcomes checklist is available in <xref rid="SP1" ref-type="supplementary-material">online supplemental material 1</xref>).<xref rid="R10" ref-type="bibr">10 11</xref> Our manuscript describes key elements of the PeRiOperative Glucose PRAgMatic (PROGRAM) trial protocol and statistical analysis plan.</p>
              <supplementary-material id="SP1" position="float" content-type="local-data">
                <object-id pub-id-type="doi">10.1136/bmjopen-2023-072745.supp1</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="SS1" xlink:href="bmjopen-2023-072745supp001.pdf" content-type="local-data"/>
                </p>
              </supplementary-material>
              <fig position="float" id="F3">
                <label>Figure 3</label>
                <caption>
                  <p>Milestones and timeline of the study in accordance with Standard Protocol Items: Recommendations for Interventional Trials Outcomes guidelines.</p>
                </caption>
                <graphic xlink:href="bmjopen-2023-072745f03" position="float"/>
              </fig>
              <sec id="s2-1">
                <title>Study design and intervention</title>
                <p>The PROGRAM trial is a prospective, unblinded, pragmatic, sequential and repeated cross-over trial conducted in the operating rooms (ORs), postoperative anaesthesia care unit (PACU) and intensive care unit with periods of time for wash out, control and study intervention at Vanderbilt University Medical Center (VUMC) in Nashville, Tennessee, USA. This multiple cross-over study is intended to limit the errant detection of secular institutional trends. The PROGRAM trial protocol was approved by the VUMC Institutional Review Board (IRB) (IRB, 220991). The trial protocol was also registered with ClinicalTrials.gov on 21 June 2022, prior to initiation of study participants’ enrolment on 5 October 2022 (ClinicalTrials.gov identifier: NCT05426096).</p>
                <p>The PROGRAM trial will assess the effect of an AIDR containing departmental insulin dosing guidelines that is triggered during anaesthetic care in the intraoperative portion of the EHR. We believe that the AIDR will influence anaesthesia providers to appropriately dose insulin and we hypothesise that this tool will result in improved glucose control in surgical patients at high risk for hyperglycaemia. The perioperative AIDR that will be implemented in the study was developed based on clinical practice parameters (practice standards, practice guidelines, consensus statements and practice advisories) with a focus on perioperative glucose control and management.<xref rid="R3" ref-type="bibr">3 12–15</xref> Consistent with the standard practice of the VUMC Department of Anesthesiology, this practice advisory was posted on the Center for Evidence Based Anesthesia (CEBA) website, and it was also made accessible through a link listed in the EHR under the in-built application of ‘I-care’ guidelines. (<xref rid="F4" ref-type="fig">figure 4</xref>) A complete list of data elements and definitions of primary and secondary outcomes can be found in the <xref rid="SP1" ref-type="supplementary-material">online supplemental file 2</xref>.</p>
                <fig position="float" id="F4">
                  <label>Figure 4</label>
                  <caption>
                    <p>Institutional practice advisory for perioperative glucose and insulin guidelines. The institutional practice advisory will be posted on the Department of Anesthesiology Center for Evidence Based Anesthesia (CEBA) website, and it will be also made accessible through a link listed in the electronic health record (EHR) under the in-built application of ‘I-care’ guidelines. BG, Blood Glucose; T2DM, Type 2 Diabetes Mellitus; T1DM, Type 1 Diabetes Mellitus; DM, Diabetes Mellitus; DKA, Diabetic Ketoacidosis; HR, Hour.</p>
                  </caption>
                  <graphic xlink:href="bmjopen-2023-072745f04" position="float"/>
                </fig>
                <p>The AIDR delivers departmental guidelines to providers in the intraoperative portion of the EHR. When a patient meets the eligibility criteria (listed below), the AIDR will provide a notification through the EHR by opening a pop-up reminder at regular intervals (<xref rid="F2" ref-type="fig">figure 2</xref>). The provider is not forced to follow the recommendations of the insulin dosing AIDR, and they are able to dismiss the reminder without penalty. In addition, the insulin dosing guidelines will continue to be available to all providers under the CEBA guidelines website via a link in the ‘I-care’ application from the EHR (<xref rid="F4" ref-type="fig">figure 4</xref>). Prior to broad implementation of the insulin dosing AIDR, a volunteer group of 12 anaesthesia providers (attendings, resident doctors, certified registered nurse anaesthetists (CRNAs)) trialled the AIDR in the intraoperative clinical setting. A formal survey composed of structured and unstructured data fields was administered to the volunteers soliciting feedback on the tool. All the volunteers responded to the survey and no significant concerns were noted that prompted structural changes the tool.</p>
                <p>Given the pragmatic nature of our study the eligibility criteria for enrolment are broad. The mode of delivery of the proposed intervention is embedded in routine perioperative care and executed by anaesthesia providers, and data collection focuses on process related and clinical outcomes relevant to the care of surgical patients at high risk for hyperglycaemia.<xref rid="R16" ref-type="bibr">16</xref>
</p>
              </sec>
              <sec id="s2-2">
                <title>Patient and public involvement</title>
                <p>Since the proposed intervention is embedded in routine perioperative care and delivered by anaesthesia providers, no specific materials were prepared and used to communicate about the study with patients and families.</p>
              </sec>
              <sec id="s2-3">
                <title>Study site and population</title>
                <p>The PROGRAM trial is being conducted in the Vanderbilt University Adult Hospital Main ORs, Medical Centre East and Gynaecological (4S) ORs at VUMC.</p>
                <p>The inclusion criteria are as follows:</p>
                <list list-type="order">
                  <list-item>
                    <p>Patients:</p>
                    <list list-type="order">
                      <list-item>
                        <p>All ages.</p>
                      </list-item>
                      <list-item>
                        <p>Scheduled for elective or emergency cardiac and non-cardiac surgery procedures.</p>
                      </list-item>
                      <list-item>
                        <p>At least one of the following two conditions are met:</p>
                        <list list-type="order">
                          <list-item>
                            <p>A documented diagnosis of diabetes type 1 or diabetes type 2, without a recorded intraoperative measurement of glucose within the last 2 hours.</p>
                          </list-item>
                          <list-item>
                            <p>An insulin administration within the last 12 hours without a recorded measurement of blood glucose within the last hour.</p>
                          </list-item>
                        </list>
                      </list-item>
                    </list>
                  </list-item>
                  <list-item>
                    <p>Anaesthesia providers</p>
                    <list list-type="order">
                      <list-item>
                        <p>Any in-OR anaesthesia provider of eligible patients. The number of expected anaesthesia providers involved in the trial is approximately 500 providers.</p>
                      </list-item>
                    </list>
                  </list-item>
                </list>
                <p>The exclusion criteria:</p>
                <list list-type="order">
                  <list-item>
                    <p>Any patient or anaesthesia provider who does not meet the above specified inclusion criteria.</p>
                  </list-item>
                </list>
                <p>The time of enrolment for the trial (ie, ‘time zero’) is the time of ‘anaesthesia start time’, when the patient is met by a member of the anaesthesia provider team assumes anaesthesia care of the patient.</p>
              </sec>
              <sec id="s2-4">
                <title>Cross-over design and intervention allocation</title>
                <p>The 12-month period of enrolment in the PROGRAM trial is divided into four 12-week blocks. During intervention blocks in cases where the patient meets eligibility criteria, the anaesthesia providers periodically receive AIDR at regular reminder intervals. During control blocks of the trial, the providers will not receive the AIDR notifications, but they will continue to receive the glucose monitoring CDS reminder. They will have access to the insulin dosing guidelines via a link in the ‘I-care’ application from the EHR. The trial will begin with a 12-week control block after which, the AIDR will be activated for a period of 12 weeks. The first 2 weeks of this period will serve as a wash-out, followed by 10 weeks of intervention. After the first 12-week intervention period, the AIDR will be switched off for 12 weeks (2-week wash-out, 10-week control period), which will be followed by the last 12-week intervention block of the trial (2-week wash-out, 10-week intervention period) (<xref rid="F5" ref-type="fig">figure 5</xref>). The trial was started on 5 October 2022 and the trial is currently ongoing.</p>
                <fig position="float" id="F5">
                  <label>Figure 5</label>
                  <caption>
                    <p>Study outline.</p>
                  </caption>
                  <graphic xlink:href="bmjopen-2023-072745f05" position="float"/>
                </fig>
                <p>Randomisation was not feasible at either the provider or patient level. In our anaesthesia care team model, an attending anaesthesiologist supervises CRNAs, anaesthesiology resident or fellow physicians and student registered nurse anaesthetists (SRNAs). Randomisation at the provider level was not possible because our staffing model would result in combinations of attending anaesthesiologists and CRNAs, SRNAs and residents from conflicting study groups. Randomisation at the patient level was not feasible out of concerns about randomly and repeatedly withholding a reminder tool on a case-by-case basis. As providers depend on reminders to reduce cognitive burden, we chose to minimise the number of times that the reminder was taken away from providers to the single transition from first experimental to second control period.</p>
              </sec>
              <sec id="s2-5">
                <title>Wash-out periods</title>
                <p>The first 12-week block of the control period will be followed by a 2-week wash-out period, at the beginning of which the anaesthesia providers will start receiving the insulin dosing AIDR. We expect a carryover period as participants choose how they will use the tool to change their clinical practice. Similarly, after the first 10-week block of the intervention period a 2-week analytic wash-out period will follow at the beginning of which the anaesthesia providers will stop receiving the AIDR. This wash-out is designed to account for the carryover effect of the tool in reminding anaesthesia providers to use the insulin dosing guidelines.</p>
                <p>Subsequently, the cycle for the remaining 10-week blocks will repeat the 2-week wash-out period as outlined in <xref rid="F5" ref-type="fig">figure 5</xref>. Data from patients during the wash-out periods will be excluded from the primary analysis.</p>
              </sec>
              <sec id="s2-6">
                <title>Blinding</title>
                <p>Given the number of anaesthesia providers and their care team delivery model, that is, often multiple anaesthesia providers are involved in the intraoperative care of patients undergoing surgery, blinding of patients and anaesthesia providers will not be performed.</p>
              </sec>
              <sec id="s2-7">
                <title>Data collection</title>
                <p>The PROGRAM trial will use two methods for data collection to minimise observer bias: (1) automated electronic data capture of structured perioperative data recorded during routine clinical care. These data are exported daily from the institution’s EHR into the Epic Clarity, VUMC Data Warehouse and Vanderbilt Department of Anesthesiology Perioperative Data Warehouse and (2) manual data collection by study personnel. The manual data collection will be used for capturing missing information and validating the automated electronic data collection process. Our hospital uses criteria from Centers for Disease Control National Healthcare Safety Network (Atlanta, Georgia) for SSI identification and categorisation, and reports of infection are collated by a centralised team for unified reporting of SSI events across the medical centre.<xref rid="R1" ref-type="bibr">1</xref>
</p>
              </sec>
              <sec id="s2-8">
                <title>Outcomes</title>
                <sec id="s2-8-1">
                  <title>Primary outcome</title>
                  <p>The primary outcome of the study is the occurrence of hyperglycaemia (glucose &gt;180 mg/dL) at the first postoperative measurement (≤3 hours postoperatively). Glucose measurements represent serum glucose levels or point of care glucose testing. Patients with missing postoperative glucose measurements will be excluded from the primary analysis.</p>
                </sec>
                <sec id="s2-8-2">
                  <title>Secondary outcomes</title>
                  <p>The PROGRAM trial will have several prespecified secondary outcomes including (1) the occurrence of intraoperative glucose monitoring; (2) total administered intraoperative insulin doses in units; (3) the magnitude of intraoperative hyperglycaemia, which is defined as the product of time and glucose level when glucose is greater than 180 mmol/dL (the area outside of normoglycaemia); (4) the serum glucose (mg/dL) at first postoperative measurement (≤3 hours postoperatively) and (5) the rate of surgical site infection (SSI).</p>
                </sec>
                <sec id="s2-8-3">
                  <title>Safety outcomes</title>
                  <p>The safety outcomes are the occurrence of hypoglycaemia (glucose &lt;60 mg/dL (3.34 mmol/L)) at the first postoperative measurement (≤3 hours postoperatively), intraoperative hypoglycaemia (glucose &lt;60 mg/dL (3.34 mmol/L)) as well as intraoperative and first postoperative hypokalaemia (mild: potassium &lt;3.5 mEq/L–3.0 mEq/L; severe &lt;3.0 mEq/L).</p>
                </sec>
              </sec>
              <sec id="s2-9">
                <title>Statistical analysis and reporting</title>
                <sec id="s2-9-1">
                  <title>Sample size estimation and power calculation</title>
                  <p>Based on the data from patients who underwent surgery at VUMC, it was estimated that the percentage of patients with hyperglycaemia at the first PACU glucose measurement is 0.42 (0.30, 0.55) (<xref rid="SP1" ref-type="supplementary-material">online supplemental material 3</xref>). According to that data, after excluding 36% of patients with missing postoperative glucose, our accrual rate is 95 subjects per week. After excluding patients recruited during the wash-out periods, this will allow us to recruit 2090 subjects during the 22 weeks of the control period and 1900 subjects during the 20 weeks of the intervention period, totalling approximately 3990 patients.</p>
                  <p>With this sample size, and the percentage of hyperglycaemic patients in the control group of 42%, we will be able to detect true failure rates of 0.38 and 0.46 (a 4.0% absolute decrease or increase) in exposed subjects with power of 80%. We believe this difference is clinically relevant. The type I error probability associated with the test of the null hypothesis that the risk of hyperglycaemia is equal in the intervention and control groups is 5%. Even if the proportion of hyperglycaemic patients in the control group is 0.54, the detectable hyperglycaemia rates in exposed subjects are 50% or 58% (4% absolute decrease or increase) with the power of 80%.</p>
                </sec>
                <sec id="s2-9-2">
                  <title>Data and safety monitoring board and interim analysis</title>
                  <p>An independent data and safety monitoring board (DSMB) oversees the trial. A single planned interim safety analysis will occur after the first experimental period. We will report the rate of hypoglycaemia in the control and intervention groups. The DSMB is composed of two physicians outside the study institution with expertise in anaesthesiology clinical practice and clinical research and one biostatistician. The DSMB has the power to direct early stopping of the trial based on safety concerns.</p>
                </sec>
                <sec id="s2-9-3">
                  <title>Statistical analysis</title>
                  <p>The reporting of statistical results will adhere to the guidelines provided in the SPIRIT-Outcomes statements.<xref rid="R10" ref-type="bibr">10 11</xref> Variables will be summarised using mean±SD or median (IQR) for continuous variables and percentage for proportions. Unadjusted comparisons of patients in control and intervention groups will be performed using the Wilcoxon rank-sum test or Pearson χ<sup>2</sup> test, as appropriate. The differences between the control and exposure groups will be summarised using standardised differences with Mahalanobis distance method or categorical variables.<xref rid="R17" ref-type="bibr">17</xref>
</p>
                  <p>To test the primary hypothesis of whether the intervention reduces the rate of postoperative hyperglycaemia, we will fit logistic regression with hyperglycaemia (yes/no) as an outcome and intervention (control/intervention), time period (first/second round of control and intervention periods), and interaction of intervention and time period as the main covariates. The model will be adjusted for demographics (age, sex, body mass index, race and ethnicity (Hispanic, non-Hispanic black, Asian, non-Hispanic white, other)), clinical characteristics: (American Society of Anesthesiologist Physical Status Classification,<xref rid="R18" ref-type="bibr">18</xref> diagnosis of type 1 diabetes, diagnosis of type 2 diabetes, last preoperative haemoglobin A1C (within 3 months prior to surgery), the use of insulin at baseline) and surgery characteristics: (surgery type, surgery service line, emergent/urgent case designation, duration of surgery). Continuous covariates will be modelled with restricted cubic splines with four knots.<xref rid="R19" ref-type="bibr">19</xref> We chose four knots because our expected effective sample size is large enough to accommodate additional df and is a good compromise between the loss of precision and flexible modelling.<xref rid="R20" ref-type="bibr">20</xref>
</p>
                  <p>Adjustment variables missing more than 50% will be excluded from the analysis.</p>
                  <p>For the rest of the variables with missing values, we will use multiple imputation by chained equations with predictive mean matching to create 10 complete datasets.<xref rid="R21" ref-type="bibr">21 22</xref> We will perform the analysis on each of these ten imputed datasets and combine the results using Rubin’s rule.<xref rid="R23" ref-type="bibr">23</xref> Based on the combined results, the overall significance of the intervention will be assessed by testing the null hypothesis that no difference exists between the intervention and control groups in either time period. The associations of intervention and outcome will be reported as adjusted ORs and their 95% CIs for each time period. To study to what extent missing data can affect our treatment estimate, we will also perform a complete-case analysis using the same modelling, testing and reporting approaches, as in the primary analysis.</p>
                  <p>Because our study does not have concurrent control/intervention groups, patients in these two groups may differ. For example, it is possible that the rate of type I and II diabetes will vary over the period of the study; and the likelihood of providers following the BPA protocol may depend on diabetes diagnosis. To compute the effect of the intervention for patients with similar characteristics, we will also analyse the main outcome after balancing the exposure groups using matching weights (MWs).<xref rid="R24" ref-type="bibr">24</xref> Similar to inverse probability weights, MWs are computed from the propensity of receiving the intervention, p, but each weight is multiplied by the minimum between p and (1−p), resulting in min(p, 1−p)/p for intervention and min(p, 1−p)/(1−p) for control subjects. Analogous to one-to-one propensity score calliper matching without replacement, this approach has an advantage over matching because it retains all observations and allows for efficient and straightforward variance estimation. Another advantage of this method is that the estimated effect of the intervention can be interpreted as an effect between subjects with similar (overlapping) propensities of intervention.<xref rid="R24" ref-type="bibr">24</xref>
</p>
                  <p>To compute MW, the propensity scores will be estimated using a logistic regression model with intervention (yes/no) as the outcome and the patient-specific and procedure-specific confounding variables listed earlier with continuous variables modelled using restricted cubic splines.<xref rid="R19" ref-type="bibr">19</xref> The model for MW will not include time period. The weights will be computed for each imputed dataset and used to estimate the effect of the intervention using weighted logistic regression with postoperative hyperglycaemia as an outcome and intervention as the covariate. To account for potential residual confounding, the model will be adjusted for the same covariates as in the primary analysis excluding the time period and the interaction of the intervention and time period. The variance of the intervention coefficient will be computed using the sandwich variance estimators.<xref rid="R25" ref-type="bibr">25</xref> The estimates from the ten models will be combined using Rubin’s rule. Based on the combined results, the association of outcome and intervention will be considered significant if the coefficient of intervention is significant. The association of the intervention with the outcome will be reported as an OR and 95% CI. The standardised differences between the covariates before and after applying MW will be reported for each imputed dataset. Successful balancing is defined as a standardised difference of&lt;0.10, which occurs, for example, when &gt;90% of categories overlap across two groups.<xref rid="R26" ref-type="bibr">26</xref>
</p>
                  <p>For the primary outcome, we will perform a sensitivity analysis that includes patients with missing postoperative glucose. In this analysis, we will assume hyperglycaemia for treated patients and no hyperglycaemia for control patients (worst-case analysis). As an additional sensitivity analysis, we will also estimate the magnitude of potential unobserved confounding using (E value) for the main effect and its lower 95% confidence limit. E value is defined as a minimum strength of association on the OR scale that an unmeasured confounder in our study must have with both exposure and outcome to explain away their putative association. Higher E values indicate robustness to unmeasured confounding.<xref rid="R27" ref-type="bibr">27</xref>
</p>
                  <p>Statistical analyses of the secondary outcomes will be performed like the primary analysis of the primary outcome (ie, using an adjusted regression with intervention, time period and intervention-time period interaction term).</p>
                  <p>In the exploratory analyses of the primary outcome, we will test for the intervention effect modification by the following baseline variables:</p>
                  <list list-type="order">
                    <list-item>
                      <p>Age.</p>
                    </list-item>
                    <list-item>
                      <p>Sex.</p>
                    </list-item>
                    <list-item>
                      <p>Race and ethnicity (Hispanic, non-Hispanic black, Asian, non-Hispanic white, other).</p>
                    </list-item>
                    <list-item>
                      <p>American Society of Anesthesiologist Physical Status Classification.<xref rid="R18" ref-type="bibr">18</xref>
</p>
                    </list-item>
                    <list-item>
                      <p>Surgery service line and type of surgery.</p>
                    </list-item>
                    <list-item>
                      <p>Emergent/urgent case designation.</p>
                    </list-item>
                    <list-item>
                      <p>Diagnosis of type 1 diabetes.</p>
                    </list-item>
                    <list-item>
                      <p>Diagnosis of type 2 diabetes.</p>
                    </list-item>
                    <list-item>
                      <p>Last preoperative haemoglobin A1C (within 3 months prior to surgery).</p>
                    </list-item>
                    <list-item>
                      <p>The use of insulin at baseline.</p>
                    </list-item>
                    <list-item>
                      <p>OR location type.</p>
                    </list-item>
                    <list-item>
                      <p>Duration of case.</p>
                    </list-item>
                  </list>
                  <p>These models will adjust for the same covariates as in the primary analysis but will not include time period. To test for effect modification by the covariate of interest, we will include an interaction term of that covariate and intervention, and then test for the significance of this interaction term.</p>
                  <p>All tests will be implemented to ensure a 5% type I error rate, and no family-wise hypotheses will be addressed. All statistical procedures will be performed using R software (<ext-link xlink:href="https://www.r-project.org" ext-link-type="uri">https://www.r-project.org</ext-link>).</p>
                </sec>
                <sec id="s2-9-4">
                  <title>Study status</title>
                  <p>The PROGRAM clinical trial has already been initiated. The first patient was enrolled on 5 October 2022. The estimated completion date for our study is 5 October 2023.</p>
                </sec>
              </sec>
            </sec>
            <sec id="s3">
              <title>Ethics and dissemination</title>
              <sec id="s3-1">
                <title>IRB approval and waivers of informed consent</title>
                <p>This study has been approved by the Vanderbilt University IRB, VUMC, Nashville, Tennessee (IRB: 220991) with a waiver of informed consent for patient participation in this study. The potential risk is minimal, and we do not anticipate any increased risks to the patients involved in this study. The insulin dosing guidelines have gained departmental approval and are currently in use. The study could not be practically conducted without a waiver of consent due to the impracticality of getting informed consent for target study population.</p>
                <p>A waiver of consent for provider participation in this study was granted by the Vanderbilt University IRB. There are no provider specific eligibility criteria. The CDS information that is being presented by the AIDR is already available to providers. The tool increases the availability of insulin dosing guidelines that have been approved by the department. There will be no direct or identifying data collected about providers. There will be no interactions with providers other than electronically through the AIDR in EPIC and an explanation of the tool at trial initiation. Provider behaviour will only be analysed secondarily based on appropriate treatment of intraoperative hyperglycaemia as evidenced by patient outcomes.</p>
              </sec>
              <sec id="s3-2">
                <title>Protocol changes</title>
                <p>Any changes to the trial protocol will be recorded on ClinicalTrials.gov according to SPIRIT-Outcomes guidelines.</p>
              </sec>
              <sec id="s3-3">
                <title>Data handling and sharing</title>
                <p>All data will be deidentified prior to analysis by trained study personal. Only vetted and approved research staff will have access to study data.</p>
              </sec>
              <sec id="s3-4">
                <title>Dissemination plan</title>
                <p>Results of this trial will be submitted to peer-reviewed journals for potential publication. In addition, results will be presented at scientific conferences.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e213">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2023-072745.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e214">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2023-072745.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> Study concept and design was done by MZ, PH, JPW, SE, MSS and MDK. Drafting of the manuscript was done by MZ, DP, SE and MDK. Critical revision of the manuscript for important intellectual content was performed by MZ, DP, PH, MDM, EH, JPW, LF, KM, RF, SE, MSS and MDK. SE and MSS were responsible for statistical analysis. Study supervision was done by PH, MDM and MDK. MZ does not have ultimate authority in study design, collection, management, analysis, interpretation of data writing of the report or the decision to submit the report for publication.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This work was supported by the Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and in part by NHLBI K23HL148640 (PI: RF) and (T32GM108554) (MZf) from the National Institutes of Health (NIH).</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ehrenfeld</surname><given-names>JM</given-names></string-name>, <string-name><surname>Wanderer</surname><given-names>JP</given-names></string-name>, <string-name><surname>Terekhov</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A perioperative systems design to improve intraoperative glucose monitoring is associated with a reduction in surgical site infections in a diabetic patient population</article-title>. <source>Anesthesiology</source><year>2017</year>;<volume>126</volume>:<fpage>431</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0000000000001516</pub-id>
<pub-id pub-id-type="pmid">28106608</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kao</surname><given-names>LS</given-names></string-name>, <string-name><surname>Meeks</surname><given-names>D</given-names></string-name>, <string-name><surname>Moyer</surname><given-names>VA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Peri-operative Glycaemic control regimens for preventing surgical site infections in adults</article-title>. <source>Cochrane Database Syst Rev</source><year>2009</year>:<elocation-id>CD006806</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD006806.pub2</pub-id><pub-id pub-id-type="pmid">19588404</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duggan</surname><given-names>EW</given-names></string-name>, <string-name><surname>Umpierrez</surname><given-names>GE</given-names></string-name></person-group>. <article-title>In reply</article-title>. <source>Anesthesiology</source><year>2017</year>;<volume>127</volume>:<fpage>900</fpage>–<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0000000000001846</pub-id>
<pub-id pub-id-type="pmid">29040104</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hua</surname><given-names>J</given-names></string-name>, <string-name><surname>Chen</surname><given-names>G</given-names></string-name>, <string-name><surname>Li</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Intensive intraoperative insulin therapy versus conventional insulin therapy during cardiac surgery: a meta-analysis</article-title>. <source>J Cardiothorac Vasc Anesth</source><year>2012</year>;<volume>26</volume>:<fpage>829</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1053/j.jvca.2011.12.016</pub-id>
<pub-id pub-id-type="pmid">22336691</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y-Y</given-names></string-name>, <string-name><surname>Hu</surname><given-names>S-F</given-names></string-name>, <string-name><surname>Ying</surname><given-names>H-M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis</article-title>. <source>BMC Endocr Disord</source><year>2018</year>;<volume>18</volume>:<elocation-id>42</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12902-018-0268-9</pub-id><pub-id pub-id-type="pmid">29929558</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guvener</surname><given-names>M</given-names></string-name>, <string-name><surname>Pasaoglu</surname><given-names>I</given-names></string-name>, <string-name><surname>Demircin</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting</article-title>. <source>Endocr J</source><year>2002</year>;<volume>49</volume>:<fpage>531</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1507/endocrj.49.531</pub-id>
<pub-id pub-id-type="pmid">12507271</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gandhi</surname><given-names>GY</given-names></string-name>, <string-name><surname>Nuttall</surname><given-names>GA</given-names></string-name>, <string-name><surname>Abel</surname><given-names>MD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery</article-title>. <source>Ann Intern Med</source><year>2007</year>;<volume>146</volume>:<fpage>233</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-146-4-200702200-00002</pub-id>
<pub-id pub-id-type="pmid">17310047</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Griesdale</surname><given-names>DEG</given-names></string-name>, <string-name><surname>de Souza</surname><given-names>RJ</given-names></string-name>, <string-name><surname>van Dam</surname><given-names>RM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data</article-title>. <source>CMAJ</source><year>2009</year>;<volume>180</volume>:<fpage>821</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.090206</pub-id>
<pub-id pub-id-type="pmid">19318387</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>G</given-names></string-name>, <string-name><surname>Dietz</surname><given-names>CJK</given-names></string-name>, <string-name><surname>Freundlich</surname><given-names>RE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The impact of an intraoperative clinical decision support tool to optimize perioperative Glycemic management</article-title>. <source>J Med Syst</source><year>2020</year>;<volume>44</volume>:<elocation-id>175</elocation-id>. <pub-id pub-id-type="doi">10.1007/s10916-020-01643-1</pub-id><pub-id pub-id-type="pmid">32827095</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname><given-names>A-W</given-names></string-name>, <string-name><surname>Tetzlaff</surname><given-names>JM</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>SPIRIT 2013 statement: defining standard protocol items for clinical trials</article-title>. <source>Ann Intern Med</source><year>2013</year>;<volume>158</volume>:<fpage>200</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-158-3-201302050-00583</pub-id>
<pub-id pub-id-type="pmid">23295957</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Butcher</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Monsour</surname><given-names>A</given-names></string-name>, <string-name><surname>Mew</surname><given-names>EJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Guidelines for reporting outcomes in trial protocols</article-title>. <source>JAMA</source><year>2022</year>;<volume>328</volume>:<fpage>2345</fpage>. <pub-id pub-id-type="doi">10.1001/jama.2022.21243</pub-id><pub-id pub-id-type="pmid">36512367</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association Professional Practice Committee</collab></person-group>. <article-title>16. diabetes care in the hospital: standards of medical care in diabetes—2022</article-title>. <source>Diabetes Care</source><year>2022</year>;<volume>45</volume>:<fpage>S244</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.2337/dc22-S016</pub-id>
<pub-id pub-id-type="pmid">34964884</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Korytkowski</surname><given-names>MT</given-names></string-name>, <string-name><surname>Muniyappa</surname><given-names>R</given-names></string-name>, <string-name><surname>Donihi</surname><given-names>AC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an endocrine society clinical practice guideline</article-title><source>J Clin Endocrinol Metab</source><year>2022</year>;<volume>107</volume>:<fpage>e4276</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1210/clinem/dgac479</pub-id>
<pub-id pub-id-type="pmid">35962778</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seisa</surname><given-names>MO</given-names></string-name>, <string-name><surname>Saadi</surname><given-names>S</given-names></string-name>, <string-name><surname>Nayfeh</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A systematic review supporting the endocrine society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures</article-title>. <source>J Clin Endocrinol Metab</source><year>2022</year>;<volume>107</volume>:<fpage>2139</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1210/clinem/dgac277</pub-id>
<pub-id pub-id-type="pmid">35690929</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colunga-Lozano</surname><given-names>LE</given-names></string-name>, <string-name><surname>Gonzalez Torres</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Delgado-Figueroa</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus</article-title>. <source>Cochrane Database Syst Rev</source><year>2018</year>;<volume>11</volume>:<elocation-id>CD011296</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD011296.pub2</pub-id><pub-id pub-id-type="pmid">30488948</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ware</surname><given-names>JH</given-names></string-name>, <string-name><surname>Hamel</surname><given-names>MB</given-names></string-name></person-group>. <article-title>Pragmatic trials — guides to better patient care</article-title><source>N Engl J Med</source><year>2011</year>;<volume>364</volume>:<fpage>1685</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp1103502</pub-id>
<pub-id pub-id-type="pmid">21542739</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>D</given-names></string-name>, <string-name><surname>Dalton</surname><given-names>J</given-names></string-name></person-group>. <article-title>A unified approach to measuring the effect size between two groups using SAS</article-title>. <source>SAS Glob Forum</source><year>2012</year>:<elocation-id>225-2012</elocation-id>.</mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Economics Co</collab></person-group>. <source>ASA physical status classification system</source>. <comment>Available</comment>: <uri xlink:href="https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system?&amp;ct=90f3762afd490acb4695d1c1a34295daf14368cfb8a95d3f717d8af7ebcc6ed1287c4fe78d0d6092d1c9d84aeff76a26f1abb65a73044dd8ab82bfb60553a812">https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system?&amp;ct=90f3762afd490acb4695d1c1a34295daf14368cfb8a95d3f717d8af7ebcc6ed1287c4fe78d0d6092d1c9d84aeff76a26f1abb65a73044dd8ab82bfb60553a812</uri></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Helmreich</surname><given-names>JE</given-names></string-name></person-group>. <article-title>Regression modeling strategies with applications to linear models, logistic and ordinal regression and survival analysis</article-title>. <source>J Stat Soft</source><year>2016</year>;<volume>70</volume>. <pub-id pub-id-type="doi">10.18637/jss.v070.b02</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stone</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Generalized additive models]: comment</article-title>. <source>Statist Sci</source><year>1986</year>;<volume>1</volume>. <pub-id pub-id-type="doi">10.1214/ss/1177013607</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Multiple imputation with multivariate imputation by chained equation (MICE) package</article-title>. <source>Ann Transl Med</source><year>2016</year>;<volume>4</volume>:<elocation-id>30</elocation-id>. <pub-id pub-id-type="doi">10.3978/j.issn.2305-5839.2015.12.63</pub-id><pub-id pub-id-type="pmid">26889483</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Buuren</surname><given-names>S</given-names></string-name></person-group>. <article-title>Multiple imputation of discrete and continuous data by fully conditional specification</article-title>. <source>Stat Methods Med Res</source><year>2007</year>;<volume>16</volume>:<fpage>219</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1177/0962280206074463</pub-id>
<pub-id pub-id-type="pmid">17621469</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Little</surname><given-names>RJA</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>DB</given-names></string-name></person-group>. <part-title>Statistical analysis with missing data</part-title>. In: <source>Statistical Analysis with Missing Data, Second Edition</source>. <publisher-name>John Wiley &amp; Sons, Inc</publisher-name>, <year>2002</year>. <pub-id pub-id-type="doi">10.1002/9781119013563</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>L</given-names></string-name>, <string-name><surname>Greene</surname><given-names>T</given-names></string-name></person-group>. <article-title>A weighting analogue to pair matching in propensity score analysis</article-title>. <source>Int J Biostat</source><year>2013</year>;<volume>9</volume>:<fpage>215</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1515/ijb-2012-0030</pub-id>
<pub-id pub-id-type="pmid">23902694</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>P</given-names></string-name>, <string-name><surname>Redden</surname><given-names>DT</given-names></string-name></person-group>. <article-title>Small sample performance of bias-corrected sandwich Estimators for cluster-randomized trials with binary outcomes</article-title>. <source>Stat Med</source><year>2015</year>;<volume>34</volume>:<fpage>281</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1002/sim.6344</pub-id>
<pub-id pub-id-type="pmid">25345738</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Austin</surname><given-names>PC</given-names></string-name></person-group>. <article-title>Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research</article-title>. <source>Communications in Statistics - Simulation and Computation</source><year>2009</year>;<volume>38</volume>:<fpage>1228</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1080/03610910902859574</pub-id>
</mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>VanderWeele</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Ding</surname><given-names>P</given-names></string-name></person-group>. <article-title>Sensitivity analysis in observational research: introducing the E-value</article-title>. <source>Ann Intern Med</source><year>2017</year>;<volume>167</volume>:<fpage>268</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.7326/M16-2607</pub-id>
<pub-id pub-id-type="pmid">28693043</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
